CN101107240B - 用于治疗与单胺神经传递的功能障碍有关的病症的茴香脑二硫杂环戊烯硫酮和其它二硫杂环戊烯硫酮类 - Google Patents

用于治疗与单胺神经传递的功能障碍有关的病症的茴香脑二硫杂环戊烯硫酮和其它二硫杂环戊烯硫酮类 Download PDF

Info

Publication number
CN101107240B
CN101107240B CN2006800030655A CN200680003065A CN101107240B CN 101107240 B CN101107240 B CN 101107240B CN 2006800030655 A CN2006800030655 A CN 2006800030655A CN 200680003065 A CN200680003065 A CN 200680003065A CN 101107240 B CN101107240 B CN 101107240B
Authority
CN
China
Prior art keywords
phenyl
represent
disorder
representative
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800030655A
Other languages
English (en)
Chinese (zh)
Other versions
CN101107240A (zh
Inventor
B·德鲁卡齐
A·N·M·肖夫默尔
R·W·芬斯特拉
M-O·克里森
J-L·伯高特
M·乔利特
W·I·伊威马巴克尔
B·J·范福利特
M·T·M·图尔普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Publication of CN101107240A publication Critical patent/CN101107240A/zh
Application granted granted Critical
Publication of CN101107240B publication Critical patent/CN101107240B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006800030655A 2005-02-24 2006-02-17 用于治疗与单胺神经传递的功能障碍有关的病症的茴香脑二硫杂环戊烯硫酮和其它二硫杂环戊烯硫酮类 Expired - Fee Related CN101107240B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05101405.8 2005-02-24
EP05101405 2005-02-24
PCT/EP2006/060060 WO2006089861A2 (en) 2005-02-24 2006-02-17 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission

Publications (2)

Publication Number Publication Date
CN101107240A CN101107240A (zh) 2008-01-16
CN101107240B true CN101107240B (zh) 2011-02-09

Family

ID=34938805

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800030655A Expired - Fee Related CN101107240B (zh) 2005-02-24 2006-02-17 用于治疗与单胺神经传递的功能障碍有关的病症的茴香脑二硫杂环戊烯硫酮和其它二硫杂环戊烯硫酮类

Country Status (14)

Country Link
EP (1) EP1858875A2 (de)
JP (1) JP2008531519A (de)
KR (1) KR20070117607A (de)
CN (1) CN101107240B (de)
AR (1) AR055862A1 (de)
AU (1) AU2006218012A1 (de)
BR (1) BRPI0609043A2 (de)
CA (1) CA2594165A1 (de)
MX (1) MX2007010380A (de)
RU (1) RU2402543C2 (de)
SA (1) SA06270023B1 (de)
TW (1) TW200640898A (de)
UA (1) UA94579C2 (de)
WO (1) WO2006089861A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
CN102807557B (zh) * 2012-08-21 2015-02-04 苏州大学 3h-1,2-二硫环戊烯-3-硫酮类化合物及其应用
KR101438415B1 (ko) * 2013-07-25 2014-09-17 동국대학교 경주캠퍼스 산학협력단 기억력 손상의 예방 또는 개선을 위한 조구등 추출물
CN104788440B (zh) * 2015-04-03 2017-12-26 苏州大学 烟酸衍生物及其应用
FR3063640B1 (fr) * 2017-03-07 2020-10-09 Elodie Petitjean Traitement de la fibrose pulmonaire a l'aide d'un inhibiteur selectif de la production d'especes reactives de l'oxygene d'origine mitochondriale
EP3592348A1 (de) 2017-03-07 2020-01-15 Op2 Drugs Desmethylanethol-trithion-derivate zur behandlung von krankheiten im zusammenhang mit der produktion von mitochondrialen reaktiven sauerstoffspezies (ros)
CN113166127A (zh) * 2018-09-18 2021-07-23 St知识产权控股公司 4-烷基-5-杂芳基-3h-1,2-二硫杂环戊烯-3-硫酮的旋转异构异构体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1442450A (fr) * 1964-05-05 1966-06-17 Monsanto Chemicals Nouveaux composés hétérocycliques contenant du soufre
JPH089611B2 (ja) * 1988-06-20 1996-01-31 三井東圧化学株式会社 新規１，２−ジチオール−３−チオン誘導体およびそれを有効成分とする免疫調節剤
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement

Also Published As

Publication number Publication date
AR055862A1 (es) 2007-09-12
MX2007010380A (es) 2007-09-25
AU2006218012A1 (en) 2006-08-31
RU2007135184A (ru) 2009-03-27
TW200640898A (en) 2006-12-01
EP1858875A2 (de) 2007-11-28
BRPI0609043A2 (pt) 2010-11-16
RU2402543C2 (ru) 2010-10-27
WO2006089861A2 (en) 2006-08-31
CA2594165A1 (en) 2006-08-31
UA94579C2 (ru) 2011-05-25
SA06270023A (ar) 2005-12-03
CN101107240A (zh) 2008-01-16
WO2006089861A3 (en) 2006-10-26
SA06270023B1 (ar) 2010-10-12
JP2008531519A (ja) 2008-08-14
KR20070117607A (ko) 2007-12-12

Similar Documents

Publication Publication Date Title
CN101107240B (zh) 用于治疗与单胺神经传递的功能障碍有关的病症的茴香脑二硫杂环戊烯硫酮和其它二硫杂环戊烯硫酮类
CN101484424B (zh) 治疗化合物
CN102264733B (zh) 新型多巴胺d3受体配体，其制备方法及其医药用途
CN103189337A (zh) 氨基二氢化茚衍生物、包含所述氨基二氢化茚衍生物的药物组合物及其在治疗中的用途
JP2003528096A (ja) デカヒドロ−イソキノリン
CN103237788A (zh) 苯烷基胺衍生物、包含所述苯烷基胺衍生物的药物组合物及其在治疗中的用途
MX2007015678A (es) Antagonistas y agonistas de piperazina-piperidina del receptor 5-ht-1a.
JP2003525274A (ja) α２−アンタゴニストとしてのキノリン誘導体
US4282222A (en) 3-Piperidino or apiperazino-1-phenyl or 1-substituted phenyl isoquinoline and antidepressant compositions thereof
Abbhi et al. Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma
Vinaya et al. Synthesis and antileukemic activity of novel 4‐(3‐(piperidin‐4‐yl) propyl) piperidine derivatives
CN102827131A (zh) 异黄酮氨基甲酸酯类化合物、其制备方法和用途
CN100522959C (zh) 一类6-芳基-3-环氨基甲基吡喃酮类衍生物的制备及用途
CN101020659A (zh) 9－胺基烷酰胺基－1－氮杂苯并蒽酮衍生物及其合成方法和应用
JPH06509318A (ja) トロポロン誘導体ならびに虚血性疾患を予防および治療するためのその薬剤組成物
CN108623537B (zh) 含胺基侧链的芳香胺类乙酰胆碱酯酶抑制剂合成与用途
US9573921B2 (en) Substituted N, N-dimethylaminoalkyl ethers of isoflavanone oximes as H1-receptor antagonists
US9944648B2 (en) Organic compounds
US5703237A (en) N-Aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands
CN1990478B (zh) 6-芳基-3-取代亚甲基吡喃酮类化合物及其制备方法和用途
CN103242219B (zh) 2,6-二酮-哌嗪(哌啶）类衍生物及其应用
US20060194971A1 (en) Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neruotransmission
CN114957127B (zh) 一种谷氨酰胺酰基环化酶抑制剂及其制备方法与应用
CN115433166B (zh) 一种选择性丁酰胆碱酯酶抑制剂及其制备方法和应用
CN106946879B (zh) 一种用于降血脂的药物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1113929

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110209

Termination date: 20120217

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1113929

Country of ref document: HK